Dr. Scott Gottlieb was appointed July 29 as one of three deputy commissioners at the FDA, and while Wall Street likes the appointment, some medical experts say they are shocked a Wall Street insider like Gottlieb would be appointed to the job. They question whether his previous job, promoting biotech stocks to investors in a Forbes newsletter, sends the wrong signal at a time when the federal government is more closely looking at ties between Wall Street and doctors researching new drugs. Gottlieb, who doesn't see a conflict, has discontinued the newsletter and says he's cut his ties to Wall Street.

Full Story:
The Seattle Times

Related Summaries